NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT06453642 2026-03-30
GPX
Fluidx Medical Technology, Inc.
Phase NA Active not recruiting
NCT05395741 2026-03-25
Regbone
Institute of Mother and Child, Warsaw, Poland
Phase 1/2 Active not recruiting
NCT02893397 2026-03-05
Supervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT04307914 2026-03-05
FURTHER
UMC Utrecht
Phase NA Active not recruiting
NCT05038124 2026-03-05
A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT03449108 2025-11-21
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05312411 2025-11-20
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT02880319 2025-09-09
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05115331 2025-05-31
1-2 PUNCH
University of Cincinnati
Phase 3 Active not recruiting
NCT04634227 2025-05-04
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
University of Iowa
Phase EARLY_PHASE1 Active not recruiting
NCT04974008 2025-01-22
OST-164-01
Emerald Clinical Inc.
Phase 2 Active not recruiting
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting